WO2008016356A3 - Genemap of the human genes associated with psoriasis - Google Patents

Genemap of the human genes associated with psoriasis Download PDF

Info

Publication number
WO2008016356A3
WO2008016356A3 PCT/US2006/030281 US2006030281W WO2008016356A3 WO 2008016356 A3 WO2008016356 A3 WO 2008016356A3 US 2006030281 W US2006030281 W US 2006030281W WO 2008016356 A3 WO2008016356 A3 WO 2008016356A3
Authority
WO
WIPO (PCT)
Prior art keywords
psoriasis
genemap
genes associated
human genes
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/030281
Other languages
French (fr)
Other versions
WO2008016356A2 (en
Inventor
Abdelmajid Belouchi
John Verner Raelson
Walter Edward Bradley
Bruno Paquin
Quynh Nguyen-Huu
Pascal Croteau
Rene Allard
Randall David Little
Johanne Cousineau
Sophie Debrus
Tim Keith
Natali Henderson
Daniel Dubois
Eerdewegh Paul Van
Jonathan Segal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genizon Biosciences Inc
Original Assignee
Genizon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genizon Biosciences Inc filed Critical Genizon Biosciences Inc
Priority to EP06813283A priority Critical patent/EP2052088A2/en
Priority to US12/309,878 priority patent/US20100120627A1/en
Priority to PCT/US2006/030281 priority patent/WO2008016356A2/en
Publication of WO2008016356A2 publication Critical patent/WO2008016356A2/en
Anticipated expiration legal-status Critical
Publication of WO2008016356A3 publication Critical patent/WO2008016356A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to psoriasis disease and/or their response to a particular drug or drugs.
PCT/US2006/030281 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis Ceased WO2008016356A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06813283A EP2052088A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis
US12/309,878 US20100120627A1 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis
PCT/US2006/030281 WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/030281 WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Publications (2)

Publication Number Publication Date
WO2008016356A2 WO2008016356A2 (en) 2008-02-07
WO2008016356A3 true WO2008016356A3 (en) 2009-04-23

Family

ID=38997596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/030281 Ceased WO2008016356A2 (en) 2006-08-02 2006-08-02 Genemap of the human genes associated with psoriasis

Country Status (3)

Country Link
US (1) US20100120627A1 (en)
EP (1) EP2052088A2 (en)
WO (1) WO2008016356A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316169B2 (en) * 2004-12-13 2011-11-17 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8163482B2 (en) 2006-02-23 2012-04-24 Nicholas Katsanis BBS10 related diagnostic methods for Bardet-Biedl syndrome
US20120128661A1 (en) * 2006-06-23 2012-05-24 Alethia Biotherapeutics Inc. Polynucleotide and polypeptide sequences involved in cancer
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
US20110311539A1 (en) * 2007-09-17 2011-12-22 Ludwig Institute For Cancer Research Ltd Diagnosis and treatment of cancer using cancer-testis antigens
AU2009227206A1 (en) * 2008-03-18 2009-09-24 Kurume University Polypeptide and pharmaceutical composition containing the polypeptide
US20110229498A1 (en) * 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2123748A1 (en) * 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
CN102105164A (en) 2008-06-11 2011-06-22 Atyr医药公司 Thrombopoietic activity of tyrosyl-TRNA synthetase polypeptides
EP2310498A1 (en) * 2008-06-26 2011-04-20 Atyr Pharma, Inc. Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
WO2010033294A1 (en) * 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
CN104829714A (en) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 Antibodies that specifically block the biological activity of a tumor antigen
EP2186821A1 (en) * 2008-11-11 2010-05-19 Universität Ulm Protein with promoting effects for axonal growth of neurons of central nervous system
WO2010088276A2 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Polynucleotide aptamer-based cross -linked materials and uses thereof
ES2552773T3 (en) 2009-02-27 2015-12-02 Atyr Pharma, Inc. Structural reasons for polypeptides associated with cell signaling activity
GB0904382D0 (en) * 2009-03-13 2009-04-29 Univ Dundee Treatment of cell proliferation and differentiation disorders
JP5730280B2 (en) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド Compositions and methods comprising histidyl-tRNA synthetase splice variants having non-canonical biological activity
WO2010120509A2 (en) 2009-03-31 2010-10-21 Atyr Pharma, Inc. Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities
CN102575285B (en) * 2009-04-20 2014-04-02 柯蓝 Breast cancer susceptibility gene GT198 and uses thereof
US8530174B2 (en) 2009-06-05 2013-09-10 The University Of North Carolina At Chapel Hill SOGA polynucleotides and polypeptides and uses thereof
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
SMT201700063T1 (en) * 2009-09-03 2017-03-08 Medimmune Llc Type 1 interferon diagnostic
JP5695384B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
JP5695385B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
JP5695383B2 (en) 2009-10-05 2015-04-01 花王株式会社 Hair shape susceptibility gene
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
ES2535951T3 (en) 2009-12-11 2015-05-19 Atyr Pharma, Inc. Histidyl tRNA synthetases to reduce inflammation
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
FR2959230B1 (en) 2010-04-27 2016-03-25 Chanel Parfums Beaute POLYPEPTIDE EXPRESSED IN CORNEA LAYER AND USE THEREOF
US20170260235A1 (en) 2010-04-27 2017-09-14 Chanel Parfums Beaute Polypeptide expressed in the stratum corneum and use thereof
CA2797259C (en) 2010-04-27 2020-09-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CN103140233B (en) 2010-05-03 2017-04-05 Atyr 医药公司 Treatment, diagnosis and the discovery of antibody compositions related to the protein fragments of methionyl-tRNA synthetase
AU2011248357B2 (en) 2010-05-03 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
US9062301B2 (en) 2010-05-04 2015-06-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-tRNA synthetases
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103118694B (en) 2010-06-01 2016-08-03 Atyr医药公司 Discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of lysyl-tRNA synthetase
EP2593126B1 (en) 2010-07-12 2017-09-20 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
CA2804278C (en) 2010-07-12 2021-07-13 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
JP6116479B2 (en) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of glycyl-tRNA synthetase
JP5964304B2 (en) 2010-08-25 2016-08-03 エータイアー ファーマ， インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of tyrosyl-tRNA synthetase
CA2812795C (en) 2010-10-06 2021-08-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases
WO2012051568A1 (en) * 2010-10-14 2012-04-19 Translational Genomics Research Institute Identification and treatment of cancer subsets
FR2968560A1 (en) * 2010-12-13 2012-06-15 Oreal USE OF THE IDE AS A BIOMARKER OF A CONDITION OF THE SCALP
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CN104220461A (en) 2011-12-29 2014-12-17 Atyr医药公司 Aspartyl-trna synthetase-fc conjugates
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
JP2015525230A (en) * 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド Dual receptor antagonistic antigen binding protein and uses thereof
WO2014010231A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Kif20a epitope peptides for th1 cells and vaccines containing the same
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
GB201223114D0 (en) * 2012-12-21 2013-02-06 Nat Univ Ireland Novel peptide
CN114717206A (en) 2013-03-15 2022-07-08 Atyr 医药公司 Histidyl-TRNA synthetase-FC conjugates
US10501803B2 (en) * 2013-05-21 2019-12-10 Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of GATA6 and NKX2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
WO2015006437A1 (en) * 2013-07-10 2015-01-15 Majzoub Joseph A Mrap2 knockouts
CR20160156A (en) 2013-10-11 2016-11-01 Oxford Biotherapeutics Ltd CONJUGATED ANTIBODIES AGAINST LY75 FOR CANCER TREATMENT
IL301919A (en) 2015-03-27 2023-06-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
TN2018000163A1 (en) * 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
CN108463211B (en) 2015-11-16 2022-09-27 全国儿童医院研究所 Materials and methods for treating myosarcoidosis and other myonectin pathologies
US20180355432A1 (en) * 2015-12-04 2018-12-13 New York University Identification of epilepsy patients at increased risk from sudden unexpected death in epilepsy
HRP20210698T1 (en) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
CA3015277A1 (en) 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
US11597774B2 (en) 2017-05-04 2023-03-07 City Of Hope Antibody variable domains and antibody constructs
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
IL279789B2 (en) 2018-06-29 2026-04-01 Res Inst Nationwide Childrens Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CN119978090A (en) 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 New cancer antigens and methods
KR20210133242A (en) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Adeno-associated viral vector delivery of B-sarcoglycans and treatment of muscular dystrophy
EP3745404B1 (en) 2019-05-29 2024-04-03 Cell Networks GmbH Method and system for predicting coupling probabilities of g-protein coupled receptors with g-proteins
CN112080559B (en) * 2019-06-14 2023-09-01 复旦大学附属华山医院 Application of PPP1CB gene SNP site in the preparation and detection of psoriasis vulgaris susceptibility products
CN114245745A (en) 2019-06-20 2022-03-25 纪念斯隆-凯特琳癌症中心 T cell receptor targeting PIK3CA mutation and application thereof
EP3994156A1 (en) * 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
CA3150964A1 (en) 2019-08-21 2021-02-25 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
FI4034170T3 (en) 2019-10-23 2026-04-16 Cue Biopharma Inc Tgf-beta polypeptides
EP4081540A4 (en) * 2019-12-24 2024-01-31 Dyve Biosciences, Inc. TOPICAL CYCLOSPORINE FOR THE TREATMENT OF PSORIASIS AND OTHER DISEASES
EP4157350A4 (en) * 2020-05-26 2025-07-23 Cue Biopharma Inc Antigen-presenting polypeptide complexes and methods of using them
KR20230165746A (en) 2020-11-30 2023-12-05 민데라 코포레이션 Microneedle device and method, and skin condition assay
CN116670282A (en) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 Oligonucleotides targeting XBP1
WO2022226037A1 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
CA3226210A1 (en) 2021-07-05 2023-01-12 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Method for cold plasma-induced cell death in breast cancer cells by 8-oxog modification and degradation of histone mrna
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CN115381951A (en) * 2022-09-28 2022-11-25 孙良丹 Use of VEGF gene expression inhibitors in the preparation or as a formulation for the treatment of psoriasis
CN116407636B (en) * 2023-05-15 2023-10-20 徐州医科大学附属医院 Application of Lnc-CCKAR-5 in preparation of medicine for promoting diabetic wound repair
WO2025213184A1 (en) * 2024-04-05 2025-10-09 Fred Hutchinson Cancer Center Novel tcrs and neoantigens in srsf2 and zrsr2 mutated cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Affymetrix: Details for HG-U95C:65653_AT", 2 June 2008 (2008-06-02), XP008116284, Retrieved from the Internet <URL:affymetrix.com> *
WRIGHT, ALAN ET AL.: "Population choice in mapping genes for complex diseases.", NATURE GENETICS., vol. 23, 1999, pages 397 - 404, XP008107916 *
ZHOU, XIANGHONG ET AL.: "Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100 element oligonucleotide array.", PHYSIOLOGICAL GENOMICS., vol. 13, 2003, pages 69 - 78, XP002512061 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9684000B2 (en) 2010-12-16 2017-06-20 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US9995755B2 (en) 2010-12-16 2018-06-12 Genentech, Inc. Diagnosis and treatments relating to TH2 inhibition
US11226341B2 (en) 2010-12-16 2022-01-18 Genentech, Inc. Method of treating asthma using an IL-13 antibody

Also Published As

Publication number Publication date
EP2052088A2 (en) 2009-04-29
WO2008016356A2 (en) 2008-02-07
US20100120627A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
WO2008112177A3 (en) Genemap of the human genes associated with schizophrenia
WO2008118258A3 (en) Genemap of the human genes associated with adhd
WO2008067195A8 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2007025085A8 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2009026116A3 (en) Genemap of the human genes associated with longevity
WO2006138696A3 (en) Genemap of the human genes associated with longevity
WO2008085601A3 (en) Genemap of the human genes associated with asthma disease
WO2009039244A3 (en) Genemap of the human genes associated with crohn&#39;s disease
WO2008014400A3 (en) Crohn disease susceptibility gene
EP2581453A3 (en) Genetic Markers of Mental Illness
WO2004005458A3 (en) Functional sites
EP2570498A3 (en) Genetic markers of mental illness
EP2540840A3 (en) Genetic variants on CHR16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008123901A3 (en) Genemap of the human genes associated with endometriosis
WO2012018613A3 (en) Genetic make-up modifies cancer outcome
WO2006081158A3 (en) Predictive and therapeutic markers in overian cancer
WO2008055196A3 (en) Genemap of the human genes associated with male pattern baldness
Ivashchenko et al. Analysis of the polymorphic alleles of genes encoding phase 1 and phase 2 detoxication enzymes in patients with endometriosis
Wang et al. SCN8A as a novel candidate gene associated with bipolar disorder in the Han Chinese population
WO2006086748A3 (en) Genetic markers in the csf2rb gene associated with an adverse hematological response to drugs
Jin et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
Jeon et al. PDGFC, MARK3 and BCL2 polymorphisms are associated with left ventricular hypertrophy in Korean population
EP2463384A3 (en) Diagnostic kits, genetic markers and methods for SCD or SCA therapy selection
Wang et al. Ttn as a likely causal gene for QTL of alcohol preference on mouse chromosome 2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06813283

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006813283

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12309878

Country of ref document: US